Stallergenes Greer Deutschland operates as a specialized pharmaceutical company focusing on allergen immunotherapy, providing products and services for allergy diagnosis and treatment. The company targets medical professionals and patients, offering educational resources and scientific information. The website reflects a professional and consistent brand presence with clear contact information and compliance with GDPR and cookie regulations. Technically, the site is built on Drupal CMS with established frontend libraries, delivering moderate performance and good mobile optimization. Security posture is solid with HTTPS and reCAPTCHA integration, though lacking explicit security policies and some security headers. Overall, the site is trustworthy and well-maintained, supporting the company's market position in healthcare allergy treatment.
Scanned ·
NIS2 and GDPR posture
GDPR outside view
83/ 100 · Low
Checks completed
7of 7
NIS2 Art. 21(2)
a(a) Risk analysis and security policies: Not visible from outside
b(b) Incident handling: One indicator
c(c) Business continuity, backups and crisis management: Not visible from outside
d(d) Supply chain security: Not visible from outside
e(e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
f(f) Assessing the effectiveness of security measures: Not visible from outside
g(g) Cyber hygiene and security training: Not visible from outside
h(h) Cryptography and encryption: Partly checked
i(i) HR security, access control and asset management: One indicator
j(j) Multi-factor authentication and secured communications: Not visible from outside
Partly checked
One indicator
Not visible from outside
This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.
GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.
Priority findings
6 findings rated critical or high. Fix these first.
Email security
SPF, DKIM and DMARC stop others sending email that looks like it comes from your domain, a common route to phishing and invoice fraud.
Critical
No email authentication configured
Domain is vulnerable to email spoofing
What to do: Implement SPF, DKIM, and DMARC immediately
Security headers
Security headers are instructions your web server sends to every visitor’s browser. Missing ones leave visitors more exposed to attacks such as clickjacking and injected scripts.
High
Missing Strict-Transport-Security header
Forces HTTPS connections
What to do: Add "Strict-Transport-Security: max-age=31536000; includeSubDomains; preload"
This scan found 25 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.
Daily monitoring
Recommended
€25per month
TLS certificates and expiry
DNS records
SPF, DKIM and DMARC
Security headers
GDPR and NIS2 posture
Exposed services
Third-party trackers
Security score drift
Email alerts on material changes and an exportable JSON history of every change.
Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.
Results by check
Each check with its score, findings and the evidence it collected.
How this score is calculated
The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.
Counted in this score
SSL/TLS
52
Security headers
40
Email security
60
DNS health
60
Network security
20
GDPR outside view
83
Average
53
Not counted
NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.
Findings that cap the score at 49
Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.
The certificate is not trusted by browsers
The website is not served over HTTPS
A database, remote desktop, file-sharing or Telnet service is reachable from the internet
The page loads a script from a compromised source
The domain registration has expired
SPF authorises every server to send mail as the domain
Partial scans
When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.
Risk levels
Critical0–25
High26–49
Medium50–75
Low76–100
Breach exposure
Leaked credentials and lookalike domains from OffSeq Breach. The counts are free; the detailed lists are paid add-ons.
Dark web exposure
Add-on
Leaked records that mention stallergenesgreer.de, from OffSeq Breach.
No leaked records found
Breach holds no records for stallergenesgreer.de right now. New leaks arrive continuously, so monitoring on Breach alerts you if that changes.
Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.
Business context
Business profile
The company holds a medium-sized position in the healthcare sector, specializing in allergen immunotherapy. Its business model revolves around pharmaceutical research, product development, and marketing, complemented by medical education initiatives such as live CME webinars. The website links to a global parent domain, indicating a broader international presence. The target audience includes healthcare professionals and allergy patients, with content tailored accordingly. The company demonstrates compliance with European data protection laws and maintains a professional digital presence, supporting its credibility and growth potential.
Security posture
The website enforces HTTPS and uses Google reCAPTCHA to protect forms, indicating a baseline security awareness. However, the absence of visible security headers and a published security policy or incident response contact suggests room for improvement in transparency and defense-in-depth. No vulnerabilities or exposed sensitive data were detected in the analysis. The cookie consent mechanism aligns with GDPR requirements, enhancing privacy compliance. Overall, the security posture is good but could be strengthened by adopting additional best practices and publishing formal security documentation.
Recommendations
Implement HTTP security headers such as Content-Security-Policy, X-Frame-Options, and X-Content-Type-Options to enhance protection against common web attacks.
Publish a clear security policy and provide incident response contact information to improve transparency and trust.
Regularly audit and update third-party libraries and dependencies to mitigate potential vulnerabilities.
Enhance accessibility features to improve usability for all users, including those with disabilities.
Maintain and update privacy and cookie policies to reflect evolving regulations and best practices.
Automated reading of the public site. Ratings are indicative.
Business
Company
Stallergenes Greer
Description
Stallergenes Greer is a global pharmaceutical company headquartered in Baar, Switzerland, specializing in the diagnosis and treatment of allergies through research, development, and marketing of allergen immunotherapy products and services.
Key services
Allergen immunotherapy products, Medical education (CME webinars), Scientific and medical information for healthcare professionals
Website is fully accessible with no blocking or WAF challenges.
Content is professional and targeted at healthcare professionals and patients.
Strong GDPR and cookie compliance with visible consent mechanisms.
No explicit security policy or incident response contact found.
Use of modern but somewhat dated frontend libraries and Drupal CMS.
Contact information is clearly presented with physical address, phone, and email.
No suspicious or malicious content detected.
Social media presence limited to X.com (Twitter).
Technical notes
Notes
The website is built on Drupal CMS with frontend technologies including jQuery 2.2, Bootstrap 3.3.5, OwlCarousel, Video.js, and Font Awesome. While these technologies are stable, some are dated and could benefit from modernization to improve performance and security. The site demonstrates good mobile responsiveness and SEO optimization with proper meta tags and structured navigation. Hosting details are not explicitly disclosed but DNS nameservers indicate a professional setup. Performance is moderate, with potential for improvement through optimization and updated technology stacks.
Standards and sources
Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.
Reviews of this site
Share your experience with stallergenesgreer.de. Every review is verified by email and published after moderation.
Community rating
No published reviews yet. Be the first to review stallergenesgreer.de.